Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound;Asociación entre la concentración plasmática de proteína C reactiva y el volumen de hiperplasia neointimal en pacientes tratados con implante de stent liberador de zotarolimus. Análisis volumétrico con ecografía intracoronaria tridimensional

Revista Espanola de Cardiologia

Volumn 60, Issue 9, 2007, Pages 923-931

  Lasave, Leandro I ^a   Abizaid, Alexandre A C ^a,b   Maia, Julio Paiva ^a   Costa Jr , José De Ribamar ^a   Feres, Fausto ^a   Mattos, Luiz A ^a   Abizaid, Andrea S ^a   Siqueira, Dimytri A ^a   Tanajura, Luiz F ^a   Staico, Rodolfo ^a   De Andrade, Pedro Beraldo ^a   Braga, Sérgio N ^a   Sousa, Amanda G M R ^a   Sousa, J Eduardo ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b NONE   (Brazil)

Author keywords

C reactive protein; Stent; Ultrasound

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; IMMUNOMODULATING AGENT; TICLOPIDINE; ZOTAROLIMUS; ABT 578; DRUG DERIVATIVE; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IMPLANTATION; INTRAVASCULAR ULTRASOUND; LINEAR REGRESSION ANALYSIS; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; THREE DIMENSIONAL IMAGING; CORONARY BLOOD VESSEL; DRUG DELIVERY SYSTEM; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; HYPERPLASIA; INTIMA; MIDDLE AGED; PATHOLOGY; STENT;

C-REACTIVE PROTEIN; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPERPLASIA; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; SIROLIMUS; STENTS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 35748980303     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13109645     Document Type: Article

References (42)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin MA, et al. Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with the novo native coronary artery lesions. N Engl J Med. 2002;346:1773-80.
2. Serruys P, Degertekin M, Tanabe K, Abizaid A, Sousa E, Colombo A, et al. Intravascular ultrasound findings in the multicenter, randomized, double blind RAVEL trial. Circulation. 2002;106:798-803.
3. Serruys PW, Kutryk M, Ong A. Drug therapy: Coronary-Artery Stents. N Engl J Med. 2006;354:483-95.
4. Biasucci L, Biondi-Zocai G. Preprocedural C-reactive protein for risk prediction before percutaneous coronary intervention: A European perspective. Clin Chem. 2004;50:1492-4.
5. Ridker P. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-8.
6. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome. Insights from therapeutic interventions. J Am Coll Cardiol. 2005;46:1978-85.
7. Kornowski R, Hong M, Tio F, Bramwell O, Wu H, Leon MB. Instent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-30.
8. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104:2228-35.
9. Forrester J, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-69
10. Farb A, Weber D, Kolodgie F, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-80.
11. Moreno P, Bernardi V, Lopez-Cuellar J, Newell J, McMellon C, Gold H, et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation. 1996;94:3098-102.
12. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrio A, Chiariello L, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998;82:515-8.
13. Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, et al. Comparison of effects of drug-eluting stents versus bare-metal stents on plasma C-reactive protein levels. Am J Cardiol. 2005;96:1384-8.
14. Buffon A, Liuzzo G, Biasucci L, Pasqualetti P, Ramazzotti V, Rebuzzi A, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512-21.
15. Walter D, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher A. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839-46.
16. Horne B, Muhlestein J, Strobel G, Carlquist J, Bair T, Anderson J. Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. Am Heart J. 2002;144:491-500.
17. Rittersma S, de Winter R, Koch K, Schotborgh C, Bax M, Heyde G, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem. 2004;50:1589-96.
18. Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, et al. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J. 2005;69:1477-83.
19. DuVall M, Ji Q, Clifford A, Barry CM, Nowak SA, Sabaj KM, et al. ABT-578 elution profile and arterial penetration using the Zo-Maxx drug-eluting stent [Abstract]. Am J Cardiol. 2004;94:223E.
20. Lasave LI, Costa JR Jr, Abizaid AA, Feres F, Tanajura LF, Staico R, et al. A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx®) and the non-drug-eluting TriMaxx® stent. J Invasive Cardiol. 2007;19:303-8.
21. Mintz G, Nissen SE, Anderson W, Bailey S, Erbel R, Fitzgerald P, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-92
22. Meredith IT, Ormiston J, Whitbourn R. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in the novo native coronary artery lesions: ENDEAVOR I Trial. Eurointervention. 2005;1:157-64.
23. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, Double-Blind, Multicenter study of the Endeavor Zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Endeavor II trial. Circulation. 2006;114:798-806.
24. Welt F, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769-76.
25. Yeh E, Willerson J. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370-1.
26. Pearson T, Mensah G, Alexander R, Anderson JL, Cannon RO, Criqui M. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
27. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
28. Biasucci L, Liuzzo G, Grillo R, Caliguri G, Rebuzzi A, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:865-70.
29. Morrow D, Rifai N, Antman E, Weiner D, McCabe C, Cannon C, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460-5.
30. Mueller C, Buettner H, Hodgson J, Marsch S, Perruchoud A, Roskamm H, et al. Inflammation and log-term mortality after non-ST-elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105:1412-5.
31. Zebrack J, Muhlestein J, Home B, Anderson J, for the Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 2002;39:632-7.
32. Abbate A, Biondi-Zoccai G, Brugaletta S, Liuzzo G, Biasucci L. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med. 2003;3:377-85.
33. Anderson J, Muhlestein J. Restenosis after coronary intervention: Narrowing C-reactive protein's prognostic potential? Am J Med. 2003;115:147-9.
34. Angioi M, Abdelmouttaleb I, Rodriguez R, Almone-Gastin I, Adjalla C, Gueant J, et al. Increased C-reactive protein levels in patients with in-stent restenosis and its implications. Am J Cardiol. 2001;87:1189-93.
35. Jeong W, Jeong M, Kim K, Lee S, Park O, Yum J, et al. An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention. Korean J Intern Med. 2003;18:154-60.
36. Rahel B, Visseren F, Suttorp M, Plokker T, Kelder J, de Jongh B, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60:36-40.
37. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J. 2005;150:344-50.
38. Zairis M, Ambrose J, Manousakis S, Stefanidis A, Papadaki O, Bilianou H, et al, for the GENERATION study group. The impact of plasma level of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. J Am Coll Cardiol. 2002;40:1375-82.
39. Ishikawa T, Hatakeyama K, Imamura T, Date H, Shibata Y, Hikichi Y, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol. 2003;91:287-92.
40. Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 2005;46:239-45.
41. Lasave LI, Abizaid AS, Abizaid A, Feres F, Staico R, Mattos LA, et al. Correlation between QCA late lumen loss and IVUS late neointimal hyperplasia in patients treated with coronary stent implantation [Abstract]. Am J Cardiol. 2006;98:97M.
42. Mintz G, Hong MK, Raizner A, Lee CW, Kim JJ, Escolar E, et al. Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents. Am J Cardiol. 2005;95:105-7.